portunities. While at Groundswell Advisors, he served as acting chief executive officer of Unity Pharma, consulted to numerous small biotech companies, and served on the board of directors of Seredigm Corp. Prior to establishing Groundswell, Jay spent ten years at Amgen Inc. where he served in various senior business development roles, including founder and Managing Director of Amgen Ventures, and earlier as head of Corporate Development. His track record includes such notable completed transactions as the acquisitions of Immunex and Tularik as well as numerous other business development efforts totaling over $15 billion in value. Before joining Amgen, Jay spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences.
He received an M.B.A. at Northeastern University and a B.S. in Physiology and Neuroscience from the University of California, San Diego.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify f
Page: 1 2 3 4 Related biology technology :1
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Orexigen(R) Therapeutics to Speak at Upcoming Conferences2
. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results3
. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program4
. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 20085
. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference6
. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints7
. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)8
. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results9
. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain10
. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders11
. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences